Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
It's all over the LSE boards, so it doesn't really matter that much , does it Knowlesi ?
It's harmless stuff,so why concern yourself with it? Time to get on with your life methinks!
Morning Chelsea
Perhaps, slightly adjusting on Paul Simon, he only sees what he wants to see, and disregards the rest ?
Why are you sorry ?
I don't think anybody on this board thinks otherwise !
Informe, informe, they've all got it informe!!
Yaaaaaaaaaawn!!
"Prof Durrant does not have a controlling interest so would not be able to prevent it."
She does, particularly if she doesn't want to be part of any deal, she can take her toys out !
Especially as you didn't respond with the same old, same old!
You still here....move along!
Don't think C7 needs any help to explain, but he doesn't say that!!
Reads a bit like somebody has been on the hard stuff very early
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, notes today’s press release from Cancer Research UK announcing the winners of its Grand Challenge award.
The Grand Challenge aims to revolutionise how cancer is diagnosed, prevented and/or treated by providing international multi-disciplinary teams the freedom to evaluate novel approaches, at scale, in the pursuit of life changing discoveries. Scancell congratulates the winners of the Award and was delighted that Project Blueprint, “Eradicating Established Tumours with Unique Cancer Vaccines”, a proposal submitted by the Company together with BioNTech, Genentech and ISA Pharmaceuticals, was shortlisted.
Project Blueprint was devised to investigate the potential of cancer vaccines, based on treatment with Modi-3, a product generated from Scancell's Moditope® platform, alongside vaccines targeting new mutations within individual patient tumours, for the treatment of virtually all cancers. Notwithstanding the result of the Award, Scancell and its collaboration partners remain committed to the ultimate objective of eliminating tumours by treating patients with such therapeutic vaccine approaches.
Prof. Lindy Durrant, Chief Scientific Officer, Scancell, said:
“We would like to congratulate the winners of Cancer Research UK’s Grand Challenge, and to thank Cancer Research UK for putting the challenge forward to some of the best researchers in the world. The shortlisting of our proposal represents a significant scientific endorsement of Scancell’s technology and the team remains committed to meeting the challenges of improving cancer vaccines for all patients.
Scancell continues to be funded to initiate the planned phase 2 clinical study for our lead ImmunoBody®, SCIB1, and to advance our lead Moditope® vaccine, Modi-1, towards the clinic, and this remains our core focus for the immediate future.”
Prof. Kees Melief, Chief Scientific Officer, ISA pharmaceuticals, said:
“We are pleased to have reached the final stages of the Grand Challenge with our approach to building a blueprint for effective personalised therapies for patients with cancer. Expansion of the specific immune response to a patient’s cancer has enormous potential to synergize with existing cancer therapies without added toxicity. We will continue to discuss how we may work together in the future to achieve this goal.”
Onwards and upwards
When will people get it into their heads that MM's have no way of manipulating the bought and sold figures shown, it's done on an average of the prices paid by the LSE computer!
From a restricted flow it is Malkster
Not through my broker they aren't!
Still 8.212 !
Lapping up the short term panic sellers, it'll be back up again by 16:30!
"Spitting dummies" may well come from our reporter at the scene, and potentially no news for this board
!
The sp finish was 3 hours later than the 2 buys!
Certainly look like buys,selling at thet time was 8p!
ifonly, explain ?